MA55627A - Agonistes de glp-1r et leurs utilisations - Google Patents
Agonistes de glp-1r et leurs utilisationsInfo
- Publication number
- MA55627A MA55627A MA055627A MA55627A MA55627A MA 55627 A MA55627 A MA 55627A MA 055627 A MA055627 A MA 055627A MA 55627 A MA55627 A MA 55627A MA 55627 A MA55627 A MA 55627A
- Authority
- MA
- Morocco
- Prior art keywords
- glp
- agonists
- Prior art date
Links
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019082381 | 2019-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55627A true MA55627A (fr) | 2022-02-16 |
Family
ID=72750961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055627A MA55627A (fr) | 2019-04-12 | 2020-04-10 | Agonistes de glp-1r et leurs utilisations |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230278991A1 (fr) |
| EP (1) | EP3953344A4 (fr) |
| JP (1) | JP2022527607A (fr) |
| KR (1) | KR20210152513A (fr) |
| CN (1) | CN113853371B (fr) |
| AU (1) | AU2020256647A1 (fr) |
| BR (1) | BR112021020335A2 (fr) |
| CA (1) | CA3136375A1 (fr) |
| CL (1) | CL2021002649A1 (fr) |
| CO (1) | CO2021015060A2 (fr) |
| CR (1) | CR20210562A (fr) |
| CU (1) | CU20210083A7 (fr) |
| DO (1) | DOP2021000208A (fr) |
| EA (1) | EA202192684A1 (fr) |
| IL (1) | IL287128A (fr) |
| MA (1) | MA55627A (fr) |
| MX (1) | MX2021012492A (fr) |
| PE (1) | PE20220143A1 (fr) |
| SG (1) | SG11202110825WA (fr) |
| WO (1) | WO2020207474A1 (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| BR112022007627A2 (pt) | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
| CN114761395A (zh) * | 2019-12-02 | 2022-07-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| EP4097097A1 (fr) * | 2020-01-29 | 2022-12-07 | Gilead Sciences, Inc. | Composés modulateurs de glp-1r |
| KR20220156535A (ko) | 2020-02-07 | 2022-11-25 | 가셔브룸 바이오, 인크. | 헤테로사이클릭 glp-1 작용제 |
| US20230165846A1 (en) * | 2020-02-13 | 2023-06-01 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| TWI825398B (zh) * | 2020-03-18 | 2023-12-11 | 南韓商Ｌｇ化學股份有限公司 | Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法 |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021259309A1 (fr) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Agoniste du récepteur glp-1, composition pharmaceutique et utilisation associées |
| CN116323599A (zh) | 2020-08-06 | 2023-06-23 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| EP4204415A1 (fr) | 2020-08-28 | 2023-07-05 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques de glp-1 |
| WO2022068772A1 (fr) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale |
| WO2022078152A1 (fr) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | Agoniste du récepteur de glp-1, la benzimidazolone et son utilisation |
| US20230391760A1 (en) * | 2020-10-13 | 2023-12-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2023546125A (ja) * | 2020-10-14 | 2023-11-01 | キル・レガー・セラピューティクス・インコーポレーテッド | Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用 |
| CN114478497B (zh) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | 芳基烷基酸类glp-1受体激动剂及其用途 |
| EP4247804A1 (fr) * | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Composés modulateurs de glp-1r polyhétérocycliques |
| CA3200245A1 (fr) * | 2020-11-27 | 2022-06-02 | Junjun Wu | Derive de benzimidazole, son procede de preparation et son utilisation medicale |
| WO2022135572A1 (fr) * | 2020-12-25 | 2022-06-30 | 四川海思科制药有限公司 | Dérivé à cinq chaînons et dérivé cyclique à cinq chaînons et leur utilisation médicale |
| WO2022184849A1 (fr) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Agonistes de glp-1r, utilisations et compositions pharmaceutiques associées |
| EP4304711A1 (fr) * | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Composés modulateurs de glp-1r |
| US20240208952A1 (en) | 2021-03-22 | 2024-06-27 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Thiophene glp-1 receptor agonist and use thereof |
| EP4313963A1 (fr) * | 2021-03-24 | 2024-02-07 | Eccogene Inc. | Dérivés d'acide phényl- [1, 3] dioxolo [4, 5-c] pyridinyl-phényl-, phényl- [1, 3] dioxolo [4, 5-c] pyridinyl-hétéroaryl-, ou phényl- [1, 3] dioxolo [4, 5-c] pyridinyl-pipéridinyl-méthyl-oxétanylméthyl-1h-benzo [d] imidazole-carboxylique et leurs procédés d'utilisation |
| WO2022202864A1 (fr) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | Composition pharmaceutique contenant un agoniste du récepteur glp-1 comportant un cycle fusionné |
| US20240300928A1 (en) * | 2021-04-08 | 2024-09-12 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| US11858918B2 (en) | 2021-04-21 | 2024-01-02 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| IL307768A (en) * | 2021-04-21 | 2023-12-01 | Gilead Sciences Inc | Carboxy-benzimidazole GLP-1R modulator compounds |
| MX2023012918A (es) * | 2021-05-03 | 2024-03-13 | Carmot Therapeutics Inc | Agonistas del receptor del péptido 1 similar al glucagón (glp-1) de bencimidazoilo, composiciones farmacéuticas que los comprenden y métodos para su uso. |
| TWI843104B (zh) * | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| AU2022300055A1 (en) * | 2021-06-24 | 2024-01-18 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1 receptor agonist and composition and use thereof |
| EP4373821A1 (fr) * | 2021-07-21 | 2024-05-29 | Hepagene Therapeutics (HK) Limited | Modulateurs du récepteur du peptide-1 similaire au glucagon et leurs utilisations |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| JP2024529527A (ja) * | 2021-08-04 | 2024-08-06 | シャンハイ ハンソー バイオメディカル カンパニー リミテッド | シクロアルケン系誘導体調節剤、その製造方法及び応用 |
| MX2024002503A (es) * | 2021-08-30 | 2024-03-15 | Mindrank Ai Ltd | Nuevo compuesto heterociclico sustituido con aril eter como agonista de glp1r. |
| WO2023038039A1 (fr) | 2021-09-08 | 2023-03-16 | 塩野義製薬株式会社 | Médicament destiné à la prévention et au traitement de maladies liées à l'activité anti-obésité |
| KR20240073108A (ko) | 2021-10-05 | 2024-05-24 | 아스트라제네카 아베 | Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄 |
| WO2023057414A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certaines octahydrofuro 3,4-b]pyrazines utilisées en tant que modulateurs du récepteur glp-1 |
| WO2023057429A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certains 2,5-diazabicyclo[4.2.0]octanes et octahydrofuro[3,4-b]pyrazines utilisés en tant que modulateurs du récepteur glp-1 |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| CN115850296A (zh) * | 2021-12-03 | 2023-03-28 | 杭州先为达生物科技有限公司 | 一种噻吩并咪唑类化合物的晶型及其制备方法 |
| WO2023106310A1 (fr) * | 2021-12-07 | 2023-06-15 | 塩野義製薬株式会社 | Dérivé hétérocyclique aromatique ayant une activité agoniste du récepteur glp-1 |
| WO2023111144A1 (fr) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | 3-azabicyclo [3.1.0] hexanes en tant que modulateurs du récepteur glp-1 |
| WO2023111145A1 (fr) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certains 3-azabicyclo[3.1.0] hexanes utilisés en tant que modulateurs du récepteur de glp-1 |
| CN116354945B (zh) * | 2021-12-27 | 2024-08-30 | 长春金赛药业有限责任公司 | 一种稠合咪唑羧酸类化合物及其制备方法和应用 |
| WO2023130878A1 (fr) * | 2022-01-10 | 2023-07-13 | 海思科医药集团股份有限公司 | Sel agoniste du glp-1, et forme cristalline et utilisation médicale de celui-ci |
| WO2023164358A1 (fr) * | 2022-02-28 | 2023-08-31 | Ascletis Bioscience Co., Ltd. | Composés modulateurs de glp-1r |
| AU2023232184A1 (en) * | 2022-03-08 | 2024-09-26 | Guangzhou Apichope Pharmaceutical Co., Ltd. | Benzo bicyclic compound, and preparation method and application thereof |
| KR20240135652A (ko) * | 2022-05-20 | 2024-09-11 | 쳉두 띠아오 지우홍 파마수티칼 팩토리 | 벤즈이미다졸 또는 아자벤즈이미다졸 화합물, 이의 제조 방법 및 그의 용도 |
| TW202408504A (zh) * | 2022-06-23 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 噻吩[2,3-d]咪唑類化合物的鹽及其晶型和在醫藥上的用途 |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| WO2024041609A1 (fr) * | 2022-08-24 | 2024-02-29 | 广州市联瑞制药有限公司 | Composé benzo bicyclique, son procédé de préparation et son utilisation |
| WO2024051749A1 (fr) * | 2022-09-06 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | Polymorphe de composé agoniste de glp-1r, son procédé de préparation et son utilisation |
| WO2024102625A1 (fr) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Agonistes de récepteur du peptide 1 de type glucagon |
| WO2024107781A1 (fr) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Agonistes du récepteur du glucagon-like peptide 1 |
| WO2024125442A1 (fr) * | 2022-12-13 | 2024-06-20 | 杭州中美华东制药有限公司 | Nouvelle forme cristalline d'un agoniste du récepteur glp-1, son procédé de préparation, composition pharmaceutique associée et son utilisation |
| CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103221404B (zh) * | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| MX365923B (es) * | 2011-12-12 | 2019-06-20 | Celgene Int Ii Sarl | Derivados de acido carboxilico que comprenden cuatro ciclos, que actuan como moduladores del receptor del peptido 1 similar al glucagon (glp-1) para terapia de enfermedades como la diabetes. |
| PL3555064T3 (pl) * | 2016-12-16 | 2023-03-06 | Pfizer Inc. | Agoności receptora GLP-1 i ich zastosowania |
| WO2019239371A1 (fr) * | 2018-06-15 | 2019-12-19 | Pfizer Inc. | Agonistes du récepteur glp-1 et leurs utilisations |
| KR20210106447A (ko) * | 2018-11-22 | 2021-08-30 | 치루 레고르 테라퓨틱스 인코포레이티드 | Glp-1r 효능제 및 그의 용도 |
| BR112022007627A2 (pt) * | 2019-10-25 | 2022-07-12 | Gilead Sciences Inc | Compostos moduladores do glp-1r |
| CN114761395A (zh) * | 2019-12-02 | 2022-07-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| US20230165846A1 (en) * | 2020-02-13 | 2023-06-01 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
-
2020
- 2020-04-10 KR KR1020217036543A patent/KR20210152513A/ko unknown
- 2020-04-10 MX MX2021012492A patent/MX2021012492A/es unknown
- 2020-04-10 CU CU2021000083A patent/CU20210083A7/es unknown
- 2020-04-10 EA EA202192684A patent/EA202192684A1/ru unknown
- 2020-04-10 MA MA055627A patent/MA55627A/fr unknown
- 2020-04-10 CA CA3136375A patent/CA3136375A1/fr active Pending
- 2020-04-10 EP EP20788321.6A patent/EP3953344A4/fr active Pending
- 2020-04-10 CN CN202080028229.XA patent/CN113853371B/zh active Active
- 2020-04-10 BR BR112021020335A patent/BR112021020335A2/pt unknown
- 2020-04-10 WO PCT/CN2020/084203 patent/WO2020207474A1/fr active Application Filing
- 2020-04-10 SG SG11202110825WA patent/SG11202110825WA/en unknown
- 2020-04-10 AU AU2020256647A patent/AU2020256647A1/en active Pending
- 2020-04-10 JP JP2021560022A patent/JP2022527607A/ja active Pending
- 2020-04-10 CR CR20210562A patent/CR20210562A/es unknown
- 2020-04-10 PE PE2021001694A patent/PE20220143A1/es unknown
-
2021
- 2021-10-08 CL CL2021002649A patent/CL2021002649A1/es unknown
- 2021-10-10 IL IL287128A patent/IL287128A/en unknown
- 2021-10-11 DO DO2021000208A patent/DOP2021000208A/es unknown
- 2021-11-08 CO CONC2021/0015060A patent/CO2021015060A2/es unknown
-
2023
- 2023-02-24 US US18/113,859 patent/US20230278991A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3953344A1 (fr) | 2022-02-16 |
| CN113853371B (zh) | 2024-05-03 |
| CL2021002649A1 (es) | 2022-05-06 |
| PE20220143A1 (es) | 2022-01-27 |
| JP2022527607A (ja) | 2022-06-02 |
| WO2020207474A1 (fr) | 2020-10-15 |
| CO2021015060A2 (es) | 2021-11-19 |
| MX2021012492A (es) | 2021-11-12 |
| AU2020256647A1 (en) | 2021-11-18 |
| IL287128A (en) | 2021-12-01 |
| CA3136375A1 (fr) | 2020-10-15 |
| DOP2021000208A (es) | 2021-11-21 |
| US20230278991A1 (en) | 2023-09-07 |
| CN113853371A (zh) | 2021-12-28 |
| EP3953344A4 (fr) | 2023-08-09 |
| EA202192684A1 (ru) | 2021-12-28 |
| CR20210562A (es) | 2022-02-18 |
| CU20210083A7 (es) | 2022-05-11 |
| KR20210152513A (ko) | 2021-12-15 |
| BR112021020335A2 (pt) | 2021-12-14 |
| SG11202110825WA (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55627A (fr) | Agonistes de glp-1r et leurs utilisations | |
| MA54555A (fr) | Agonistes de glp-1r et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA52777A (fr) | Agents de liaison psma et utilisations correspondantes | |
| MA50502A (fr) | Adénovirus et utilisations associées | |
| MA56480A (fr) | Agonistes du récepteur glp-1 et leurs utilisations | |
| MA52414A (fr) | Anticorps agonistes de pd-1 et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
| MA50265A (fr) | Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations | |
| MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
| MA44885A (fr) | Protéines de liaison bispécifiques et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA55565A (fr) | Agents de dégradation de stat et leurs utilisations | |
| MA43417A (fr) | Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations | |
| MA56462A (fr) | Inhibiteurs de hpk1 et leurs utilisations | |
| MA53883A (fr) | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| MA46945A (fr) | Exopolysaccharides et leurs utilisations |